55 Presentations from Top Biopharma at PEGS Europe 2019

Developability Assessment to Select Candidates for Clinical Development
Anup Arumughan, PhD, Principal Scientist, Antibody Analytics, Roche

Preclinical Combinations of T Cell Bispecifics Targeting Solid Tumors and Hematological Malignancies

Marina Bacac, PhD, Head, Cancer Immunotherapy Department 2 (CIT-2), Roche Innovation Center Zurich

 

New Design of a Blast Freezer Thawer to Minimize Freeze-Thaw Associated Protein Aggregation

Karoline Bechtold-Peters, PhD, Senior Strategy and Technology Leader, Biologics Technical Development & Manufacturing, Novartis Pharma AG

 

A Development and Manufacturing Platform for Non-Platform Proteins

Matthias Berkemeyer, PhD, Associate Director, Downstream Development, NBE and Biosimilars, Biopharma Process Science Austria, Boehringer Ingelheim RCV GmbH & Co KG

 

Bispecific Target Discovery by High-Throughput Functional Screening

Pallavi Bhatta, PhD, Principal Scientist, Bispecific Target Discovery, UCB

 

Discovery of Potent Human Therapeutic Antibodies Using Phage and Yeast Display Technologies

Thomas Bouquin, PhD, Head, Biologics Research France, Centre de Recherche de Vitry/Alfortville, Sanofi

 

Targeted Antibody-Prodrugs

Ulrich Brinkmann, PhD, Expert Scientist, Large Molecule Research, Roche Pharma Research & Early Development, Roche

 

A Simple IgG-like Discovery Platform for a Complex IgG-like (1+1) Format

Régis Cebe, MSc, Scientific Technical Leader, Novartis Biologic Centre, Novartis Institute of Biomedical Research

 

Monitoring of Clearance of Lipase Host Cell Proteins in mAb Manufacturing Using a LC-MRM Quantitation Method

Rachel Chen, PhD, Scientist II, Analytical Development, Biogen

 

Combining Deep Sequencing and High Throughput B Cell Technologies to Maximize Functional Activity Guided Antibodies Discovery and Optimization

Gabriel WC Cheung, PhD, Senior Director, BioMedicine Design, Pfizer, Inc.

 

Multi-Specific Agent to Overcome Potential Resistance to Influenza

Mark Chiu, PhD, Associate Director, BioTherapeutics Analytical Development, Janssen Research & Development LLC

 

Overcoming Some Challenges in the Purification of Bispecific Antibodies
Ana Correia, PhD, Scientist, Biologics Optimization, Amgen, Inc.

 

A Novel Mucin 16 Bispecific T Cell Engaging Antibody for the Treatment of Ovarian Cancer

Alison Crawford, PhD, Senior Staff Scientist, Oncology and Angiogenesis, Regeneron Pharmaceuticals, Inc.

 

Targeted Thorium Conjugates (TTCs): A New Modality for the Treatment of Cancer Utilizing Alpha Particle-Based Radiotherapy

Alan Cuthbertson, PhD, Head of Thorium R&D, TCR, Bayer AS

 

An Integrated Approach for Optimization and Developability Assessment of Peptides Intended for Multiple-Dose Pen Devices

Andreas Evers, PhD, Senior Scientist, Synthetic Molecular Design, Integrated Drug Discovery, Sanofi

 

The Making of a Biparatopic Molecule

Fernando Garces, PhD, Senior Scientist, Biologics Optimization, Amgen, Inc.

 

The Contorsbody, a Format for Agonism: Design, Structure, Function

Guy Georges, PhD, Expert Scientist, Large Molecule Research, Roche Innovation Center Munich

 

Quantitation of HCP by Mass Spectrometry as a Method to Control the Quality of Biopharmaceuticals

Annick Gervais, PhD, Director, Analytical Development, Biologicals, UCB Pharma SA

 

Developing Bi- & Multi-Specific Immune-Modulatory Biologics to Address Unmet Needs
Tariq Ghayur, PhD, Distinguished Research Fellow, AbbVie Bioresearch Center

 

A New Platform for the Identification of Synergistic Bispecific Combinations

Elke Glasmacher, PhD, Head, Immunobiology, Large Molecule Research, pRED, Roche Innovation Center

 

Antibody Discovery for Metabolic Enzyme and Immuno-Oncology Targets

Maria Groves, PhD, Associate Director, Lab Head for the CRUK/Medimmune Alliance, AstraZeneca

 

Developability Assessment to Enable Candidate Selection of Therapeutic Proteins

Steffen Hartmann, PhD, Head, Characterization, Formulation and Bioinformatics, Novartis Pharma AG

 

Monitoring and Characterizing Aggregation Variants in Co-Formulated Biologic Products: Utilizing 2D Chromatography to Assess Aggregation

Mark Anthony Haverick, Associate Principal Scientist, Biologics Analytical R&D, MSD

 

Deep Sequencing of Natural Antibody Repertoires for Antibody Discovery and Optimization and Elucidation of Repertoire Properties

Isidro Hotzel, PhD, Senior Scientist, Antibody Engineering, Genentech, Inc.

 

Bispecific Antibodies: Discovery, Development, and Next Generation

Tomoyuki Igawa, PhD, CEO, Head, Research, Global Biologics Leader, Chugai Pharmabody Research Pte. Ltd

 

Optimization of Preclinical Safety and Efficacy of Anti-HER2/CD3

Teemu Junttila, PhD, Senior Scientist, Translational Oncology, Genentech, Inc.

 

Physicochemical Predictors of Antibody Solution Behavior

Jonathan Kingsbury, PhD, Head, Developability and Preformulation, Biologics Development, Sanofi

 

Targeting Cancer with BiTE® Antibody Constructs

Roman Kischel, MD, Director, Research, Amgen Research (Munich) GmbH

 

Tumor-Targeted 4-1BB Co-Stimulation to Boost T Cell Activity for Cancer Immunotherapy

Christian Klein, PhD, Head of Oncology Programs & Department Head of Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development

 

Humanization and Simultaneous Optimization of Monoclonal and Bispecific Antibody

Christine X. Koo, PhD, Senior Scientist 1, Lead Optimization, Chugai Pharmabody Research

 

Understanding Protein Aggregation via Computational Means

Sandeep Kumar, PhD, Senior Research Fellow, Biotherapeutics, Boehringer-Ingelheim Pharmaceuticals

 

Toward in silico Lead Discovery

Lars Linden, PhD, Director & Head, Protein Biochemistry, Bayer Healthcare AG

 

Aptamers and Enzyme Cascades as New Tools for Analytical Characterization of Biopharmaceuticals

Urs Lohrig, PhD, Lab Head, Physico-Chemical Characterisation, Novartis

 

Biophysical Screening of Unwanted Protein Interactions

Nikolai Lorenzen, PhD, Specialist, Biophysics and Formulation, Novo Nordisk A/S

 

Novel Protein A Small and Large-Scale Purification Platforms for Bispecific Antibodies

Afshin Mahmoudi, MS, Biotherapeutics, Signal Pharmaceuticals, LLC (a wholly owned subsidiary of Celgene Corp.)

 

Solution NMR Assessments of Therapeutic Protein Behavior

Mark McCoy, PhD, Principal Scientist, Discovery Chemistry – Screening, Target and Compound Profiling, MSD

 

Characterization from Developability to BLA

Jean-Michel Menet, PhD, Head, Characterization, Biologics Development/BioAnalytics, Sanofi

 

A Reliable and Automated Workflow for LC-MS MAM Analysis of Biopharmaceuticals – From High Throughput Sample Preparation to Data Evaluation

Patrick Sascha Merkle, PhD, Postdoc, Analytical Development & Characterization, Novartis Pharma AG

 

Advancing Therapeutic Protein Development Using a Novel O-Glycan-Based Conjugation Approach

Monika Papworth, PhD, Senior Scientist, Antibody Discovery and Protein Engineering, AstraZeneca

 

Precise Genome Engineering of Hybridomas for Antibody Expression and Screening

Cristina Parola, PhD, Postdoctoral Research Scientist, Biologics Research, Sanofi

 

Development of a Pre-Glycoengineered CHO-K1 Host Cell Line for the Expression of Antibodies with Enhanced Fc Mediated Effector Function

Oliver Popp, Dr. rer. nat., Principle Scientist, pRED, Large Molecule Research, Roche Diagnostics GmbH, Roche Innovation Center Munich

 

Characterization of Subvisible Particles: Old Challenges and Newest Improvements

Anacelia Rios Quiroz, PhD, Scientist, Group Leader, Particle Lab, Pharma Technical Development Biologics Europe, Hoffmann-La Roche

 

Discovery and Optimization of a Novel T Cell Bispecific for the Treatment of Solid Tumors

Adam Root, MSc, Senior Principal Scientist, BioMedicine Design, Pfizer Inc.

 

Effective Management of ADC Development and Clinical Manufacturing Including Outsourcing – A Big Pharma Perspective

Ulrich Rümenapp, PhD, Head, Launch Preparation and Coordination, Bayer AG

 

Bioconjugates: Development of an Efficient and Scalable Maleimide Linker Stabilization Method

Pegah Saremirad, PhD, Scientist, Process Development, AstraZeneca

 

Expanding the CHO CLD Toolbox to Enable Fast-Track Development of Innovative Biotherapeutics

Valerie Schmieder, PhD, Postdoctoral Researcher, BioProcess & Analytical Development Department, Boehringer Ingelheim Pharma GmbH & Co. KG

 

Begin with Quality in Mind: Identifying CQAs from Early Stage of Product Lifecycle

Archana Shah, PhD, Investigator, GlaxoSmithKline

 

Bintrafusp Alfa (M7824): A New Class of Next Generation Immune-Oncology Agent Targeting PDL-1 and TGF-Beta

Michael R. Streit, PhD, Executive Director, Cancer Epigenetics, GlaxoSmithKline

 

Strategy to Establish Clinically Relevant Specifications at Launch

John Stults, PhD, Director, Protein Analytical Chemistry, Genentech, Inc.

 

Novel Antibody Engineering to Improve Therapeutic Index of Antibody Targeting Solid Tumors

Kanako Tatsumi, PhD, Researcher, Discovery Biologics, Chugai Pharmaceutical Co. Ltd.

 

Chemometrics and Advanced Data Analytics for Particle Analysis

Jonas Hoeg Thygesen, PhD, Area Specialist, R&D Microanalysis, Novo Nordisk Pharmatech A/S

 

Study of the Impact of Proximal Chromosomal Environment Alterations Using a Targeted Integration CHO Host Cell Line

Mark Trautwein, Dr. rer. nat., Senior Scientist, Biologics Research, Bayer AG

 

Strategies to Isolate and Engineer Functional Antibodies against GPCR and Ion Channel Targets

Trevor Wilkinson, PhD, Associate Director, Antibody Discovery and Protein Engineering, AstraZeneca

 

GSK3359609- Anti-ICOS IgG4 Antibody Engineered for Optimized T Cell Agonist Effects Translating to Anti-Tumor Responses in the Clinic

Sapna Yadavilli, PhD, Associate Fellow, Precision Medicine Lead, Clinical Biomarkers and Experimental Medicine, Oncology TA, GlaxoSmithKline

 

Targeting Tumor-Associated Macrophages to Improve Cancer Immunotherapy

Minhong Yan, PhD, Principal Scientist, Molecular Oncology, Genentech, Inc.

 

Novel Strategies for the Generation of Yeast Surface Display and Phage Display Antibody Libraries

Stefan Zielonka, PhD, Associate Director, Protein Engineering & Antibody Technologies, Discovery Technologies, Global Research and Development, Merck Healthcare KGaA